William Eberley brings 15 years of biopharmaceutical expertise to his role as executive director of manufacturing science and technology at Vertex Pharmaceuticals. With a Bachelor of Science/Master of Science in biochemistry, Eberley began his career as a research scientist at Ohio State University before transitioning to industry. His experience spans roles of increasing responsibility at Bristol Myers Squibb and Sanofi Genzyme, where he supported the successful development and commercialization of several critical biologic medicines.
Since joining Vertex in 2021, Eberley has led a team of highly skilled process scientists and engineers, providing technical oversight for manufacturing operations across Vertex’s cell and gene therapy manufacturing network. His leadership has been instrumental across several disease areas of the company’s portfolio, particularly sickle cell disease, transfusion-dependent beta thalassemia and type 1 diabetes.
Eberley’s achievements include driving successful process validations for a highly complex cell therapy, resolving critical manufacturing investigations and implementing continuous process improvements to enhance yields and robustness while maintaining the highest quality standards. His innovative approach balances scientific rigor with pragmatic risk management and has begun to influence technical and regulatory approaches in the field of cell and gene therapy manufacturing in complex technical areas.
Known for his curiosity, leadership and pursuit of excellence, Eberley excels at breaking down complex problems and ensuring his team stays focused on the direct patient impact of its work. He has demonstrated a clear vision of putting patients front and center in everything that he and his team do at Vertex.